Buserelin

Origin and Structure

Buserelin is a synthetic nonapeptide analogue of gonadotropin-releasing hormone (GnRH), first developed at Hoechst AG (now Sanofi) in the mid-1970s and brought to market in the early 1980s under the trade names Suprefact and Suprecur. Its sequence — pGlu-His-Trp-Ser-Tyr-D-Ser(tBu)-Leu-Arg-Pro-ethylamide — differs from native GnRH at two positions: a D-serine(tert-butyl) substitution at position 6 that resists enzymatic cleavage, and an ethylamide replacement of the C-terminal glycinamide. Those two modifications extend the half-life roughly 20-fold and produce a compound that is between 20 and 170 times more potent than endogenous GnRH at the pituitary receptor, depending on assay conditions.

Buserelin was one of the earliest commercially successful GnRH superagonists, alongside triptorelin and leuprolide. It is typically delivered as a subcutaneous injection or an intranasal spray — the nasal route produces lower but clinically adequate plasma concentrations and is common in endometriosis protocols.

Mechanism of Action

GnRH normally drives the pulsatile release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the anterior pituitary. Buserelin exploits a counterintuitive pharmacology: continuous receptor occupancy by a GnRH agonist initially causes a "flare" — a transient LH/FSH surge lasting 1–2 weeks — followed by receptor downregulation and desensitization. After roughly 14–21 days of sustained exposure, gonadotropin output collapses and gonadal steroid production (testosterone in men, estradiol in women) falls to castrate or postmenopausal levels. This is the therapeutic endpoint for the drug's two principal indications.

Clinical Evidence and Approved Uses

Buserelin's human evidence base is substantial and spans four decades. Its main approved indications are:

• Advanced prostate cancer. By inducing chemical castration, buserelin suppresses androgen-driven tumor growth. It has been used in combination with anti-androgens to block the initial testosterone flare from worsening disease.
• Endometriosis. Sustained estradiol suppression shrinks endometrial implants and reduces pelvic pain. Treatment is typically limited to six months per course because of bone loss.
• Uterine fibroids. Preoperative buserelin reduces fibroid volume and intraoperative blood loss.
• In-vitro fertilization (IVF) protocols. Buserelin is used for pituitary downregulation before controlled ovarian stimulation, preventing premature LH surges.

The drug has never been the dominant GnRH agonist in the U.S. market — leuprolide (Lupron) took that position — but it remains widely used in Europe, Canada, and parts of Asia.

Safety Profile

Buserelin's side effects are the predictable consequences of hypogonadism: hot flashes, reduced libido, erectile dysfunction, fatigue, mood changes, and — with longer treatment — reduced bone mineral density. The initial testosterone flare in prostate cancer patients can briefly exacerbate bone pain or urinary obstruction, which is why concurrent anti-androgen therapy is standard during the first weeks. Intranasal administration can cause local nasal irritation. Injection-site reactions are mild and uncommon.

Regulatory Status and the Antagonist Shift

Buserelin is approved in numerous countries but was never marketed in the United States. It remains a prescription medicine elsewhere and is not available through research-chemical channels the way unapproved peptides are. A significant trend over the past 15 years has been the gradual displacement of GnRH agonists by GnRH antagonists — compounds like degarelix — which achieve testosterone suppression immediately without the initial flare.

The Bottom Line

Buserelin is a long-established, well-characterized prescription drug with narrow oncology and reproductive-medicine indications. It is not a wellness or longevity compound, and there are no meaningful off-label use cases outside its approved indications. For anyone studying the GnRH class, buserelin is mostly of interest as a historical reference point and as a still-used alternative where leuprolide or degarelix are less convenient.